SRSohaib Roomi

Sohaib Roomi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sohaib Roomi has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unmasking Essential Thrombocythemia in Heparin-Induced Thrombocytopenia After Coronary Artery Bypass Grafting

    by Sapna Kumari, Basanta Thapa, Sohaib Roomi, Alison Sabados, Grigori Okoev, Prasad Konda, Paul Tolerico, Nishi Patel, Omair Chaudhary, Vishal N. Shah

  • PREDICTORS OF PERMANENT PACEMAKER IMPLANTATION IN PATIENTS UNDERGOING TRANSCATHER AORTIC VALVE REPLACEMENT - A SYSTEMATIC REVIEW AND META-ANALYSIS

    by Waqas Ullah, Salman Zahid, Ramsha Zaidi, Shujaul Haq, Sohaib Roomi, Deepika Sarvepalli, Maryam Mukhtar, Atif Khan, Smitha Narayana Gowda, Nicholas Ruggiero, et al.


  • Percutaneous coronary intervention in patients with cardiac allograft vasculopathy: a Nationwide Inpatient Sample (NIS) database analysis

    by Waqas Ullah, Nishant Thalambedu, Salman Zahid, Muhammad Zia Khan, Tanveer Mir, Sohaib Roomi, David L. Fischman, Salim S. Virani, Mahboob Alam

    Cardiac allograft vasculopathy (CAV) is a major cause of heart transplant failure and mortality. The role of percutaneous coronary intervention (PCI) in these patients remains unknown. Methods: The National Inpatient Sample (NIS) (2015–2017) was queried to identify all cases of CAV. The merits of PCI were determined using a propensity-matched multivariate logistic regression model. Adjusted odds ratios (aOR) for in-hospital complications were calculated. Results: A total of 2,380 patients (PCI 185, no-PCI 21,95) with CAV were included in the analysis. There was no significant difference in the odds of major bleeding (OR 1.87, 95% CI 0.94–3.7, P = 0.11), post-procedure bleeding (P = 0.37), cardiogenic shock (OR 0.87, 95% CI 0.45–1.69, P = 0.80), acute kidney injury (uOR 0.92, 95% CI 0.68–1.24, P = 0.64), cardiopulmonary arrest (OR 0.84, 95% CI 0.34–2.11, P = 0.88), and in-hospital mortality (OR 1.59, 95% CI 0.91–2.79, P = 0.14) between patients undergoing PCI compared to those treated conservatively. A propensity-matched analysis closely followed the results of unadjusted crude analysis. Conclusion: PCI in CAV may be associated with increased in-hospital complications and higher resource utilization.


  • Open Access

    Anticoagulation in COVID-19: a single-center retrospective study

    by Sohaib Sanan Roomi, Maryum Saddique, Waqas Ullah, Shujaul Haq, Ammar Ashfaq, John Madara, Margot Boigon

    Introduction: COVID-19 induces a pro-thrombotic state as evidenced by microvascular thrombi in the renal and pulmonary vasculature. Therapeutic anticoagulation in COVID-19 has been debated and data remain anecdotal. Hypothesis: We hypothesize that therapeutic anticoagulation is associated with a reduction in in-hospital mortality, upgrade to intensive care unit, invasive mechanical ventilation, and acute renal failure necessitating dialysis by decreasing the over-all clot burden. Methods: A retrospective cohort study was done to determine the impact of therapeutic anticoagulation in hospitalized COVID-19 patients. Independent t-test and multivariate logistic regression analysis were performed to calculate mean differences and adjusted odds ratios (aOR) with its 95% confidence interval (CI) respectively. Results: A total of 176 hospitalized COVID-19 patients were divided into two groups, therapeutic anticoagulation and prophylactic anticoagulation. The mean age, baseline comorbidities and other medications used during hospitalization were similar in both groups. The aOR for in-hospital mortality (OR 3.05, 95% CI 1.15–8.10, p = 0.04), upgrade to intensive care (OR 3.08, 95% CI 1.43–6.64, p = 0.006) and invasive mechanical ventilation (OR 4.27, 95% CI 1.95–9.34, p = 0.00) were significantly lower while there was no statistically significant difference in the rate of developing acute renal failure (OR 1.87 95% CI 0.46–7.63, p = 0.64) between two groups. Conclusions: In patients with COVID-19, therapeutic anticoagulation offers a significant reduction in the rate of in-hospital mortality, upgrade to intensive medical care, and invasive mechanical ventilation. It should be preferred over prophylactic anticoagulation in COVID-19 patients unless randomized controlled trials prove otherwise.


  • Open Access

    Declining Intensive Care Unit Mortality of COVID-19: A Multi-Center Study

    by Sohaib Roomi, Syed Omar Shah, Waqas Ullah, Shan Ul Abedin, Karyn Butler, Kelly Schiers, Benjamin Kohl, Erika Yoo, Matthew Vibbert, Jack Jallo

    Declining Intensive Care Unit Mortality of COVID-19: A Multi-Center Study


  • Open Access

    Predictability of CRP and D-Dimer levels for in-hospital outcomes and mortality of COVID-19

    by Waqas Ullah, Nishanth Thalambedu, Shujaul Haq, Rehan Saeed, Shristi Khanal, Shafaq Tariq, Sohaib Roomi, John Madara, Margot Boigon, Donald C. Haas, et al.

    Systemic inflammation elicited by a cytokine storm is considered a hallmark of coronavirus disease 2019 (COVID-19). This study aims to assess the clinical utility of the C-reactive protein (CRP) an...


  • Open Access

    Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review

    by Sohaib Roomi, Waqas Ullah, Faizan Ahmed, Soban Farooq, Usama Sadiq, Asad Chohan, Munnam Jafar, Maryum Saddique, Shristi Khanal, Robert Watson, et al.

    Background: During the initial phases of the COVID-19 pandemic, there was an unfounded fervor surrounding the use of hydroxychloroquine (HCQ) and tocilizumab (TCZ); however, evidence on their efficacy and safety have been controversial. Objective: The purpose of this study is to evaluate the overall clinical effectiveness of HCQ and TCZ in patients with COVID-19. We hypothesize that HCQ and TCZ use in these patients will be associated with a reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. Methods: A retrospective cohort study was performed to determine the impact of HCQ and TCZ use on hard clinical outcomes during hospitalization. A total of 176 hospitalized patients with a confirmed COVID-19 diagnosis was included. Patients were divided into two comparison groups: (1) HCQ (n=144) vs no-HCQ (n=32) and (2) TCZ (n=32) vs no-TCZ (n=144). The mean age, baseline comorbidities, and other medications used during hospitalization were uniformly distributed among all the groups. Independent t tests and multivariate logistic regression analysis were performed to calculate mean differences and adjusted odds ratios with 95% CIs, respectively. Results: The unadjusted odds ratio for patients upgraded to a higher level of care (ie, intensive care unit) (OR 2.6, 95% CI 1.19-5.69; P=.003) and reductions in C-reactive protein (CRP) level on day 7 of hospitalization (21% vs 56%, OR 0.21, 95% CI 0.08-0.55; P=.002) were significantly higher in the TCZ group compared to the control group. There was no significant difference in the odds of in-hospital mortality, upgrade to intensive medical care, need for invasive mechanical ventilation, acute kidney failure necessitating dialysis, or discharge from the hospital after recovery in both the HCQ and TCZ groups compared to their respective control groups. Adjusted odds ratios controlled for baseline comorbidities and medications closely followed the unadjusted estimates. Conclusions: In this cohort of patients with COVID-19, neither HCQ nor TCZ offered a significant reduction in in-hospital mortality, upgrade to intensive medical care, invasive mechanical ventilation, or acute renal failure needing dialysis. These results are similar to the recently published preliminary results of the HCQ arm of the Recovery trial, which showed no clinical benefit from the use of HCQ in hospitalized patients with COVID-19 (the TCZ arm is ongoing). Double-blinded randomized controlled trials are needed to further evaluate the impact of these drugs in larger patient samples so that data-driven guidelines can be deduced to combat this global pandemic.


  • Open Access

    Is therapeutic anticoagulation improving renal outcomes in COVID-19?

    by Sohaib Roomi, Waqas Ullah, Soban Farooq, Rehan Saeed, Shujaul Haq, Ammar Ali Ashfaq

    We present three patients with COVID-19 who developed acute renal failure during hospitalization and were seen to have an improvement in their kidney function after being started on therapeutic anticoagulation with heparin (Target PTT 58–93 seconds) for varying indications (atrial fibrillation, popliteal vein thrombosis and a pulmonary embolism). Their kidney functions improved significantly following anticoagulation with a clear temporal relationship between the former and latter. Anticoagulation was held for one patient due to concern of gastrointestinal bleeding and his kidney functions worsened a day after stopping anticoagulation. D-dimer levels also improved with anticoagulation but the trend of other inflammatory markers remained unpredictable.


  • Open Access

    Complications of leadless vs conventional (lead) artificial pacemakers – a retrospective review

    by Yasar Sattar, Waqas Ullah, Sohaib Roomi, Hiba Rauf, Maryam Mukhtar, Asrar Ahmad, Zain Ali, Muhammad Shan-Ul- Abedin, M Chadi Alraies

    Background: Leadless pacemakers (LPM) are introduced in cardiovascular market with a goal to avoid lead- and pocket-associated complications due to conventional artificial pacemakers (CPM). The comparison of LPM and CPM complications is not well studied at a case by case level. Methods: Comprehensive literature was searched on multiple databases performed from inception to December 2019 and revealed 204 cases that received LPM with a comparison of CPM. The data of complications were extracted, screened by independent authors and analyzed using IBM SPSS Statistics for Windows, Version 22.0 (Armonk, NY: IBM Corp.). Results: The complications of CPM were high in comparison to LPM in terms of electrode dislodgement (56% vs 7% of cases, p-value < .0001), pocket site infection rate (16% vs 3.4%, p-value = 0.02), and a lead fracture rate (8% vs 0%, p-value = 0.04). LPMs had a statistically non-significant two-times high risk of pericardial effusion (8%) compared to CPMs (4%) with a p-value = 0.8. Conclusion: LPMs appear to have a better safety profile than CPMs. There was a low pocket site and lead-related infections in LPM as compared to CPM. However, LPM can have twice the risk of pericardial effusion than CPMs, but this was not statistically significant.


  • Open Access

    An unusual case of fungal ball on implantable cardioverter defibrillator wire and literature review

    by Hiba Rauf, Waqas Ullah, Sohaib Roomi, Asrar Ahmad, Yasar Sattar, Zain Ali, Neethu Gopisetti

    Cardiac Implantable Electronic Device (CIED) includes pacemakers and implantable cardioverter defibrillators (ICD). The device infection is classified into pocket and systemic infection. We present a case of candida fungemia secondary to dissemination from the fungal ball found on an ICD. Patient was successfully managed with IV fluconazole, ICD explantation and reimplantation. The purpose of this report is to highlight rare complications of ICD implantation and guide its clinical course and management.